The formulation of a correct diagnosis and the prescription of adequate therapies represent key aspects in planning healthcare. Diagnostic and therapeutic errors constitute a significant and unrecognized threat to patient safety. In such a context, the management of clinical risk represents a privileged observatory on healthcare since the successful implementation of these activities involves the search for preventive actions adequate to overcome the critical issues. The implementation of a virtuous litigation management system as well as a culture of safety for citizens and health professionals cannot be guaranteed by sectoral interventions but must derive from the integrated action of different skills. With this in mind, the integration of activities must aim at improving quality and safety with clinical risk management. These activities must be guaranteed through the most appropriate organizational methods based on the peculiarities of the individual health systems. Therefore, in the current state of knowledge, the acquisition of data from the different institutions is fundamental in order to adopt a shared methodology and design appropriate strategies for the reduction of errors in medicine. The need to generate evidence and recommendations useful for competitively addressing problems related to error requires the identification and use of evaluation criteria and performance indicators that can contribute to the continuous updating of technologies. Furthermore, the reduction of the knowledge gap and the implementation of surveillance systems at a multicenter level can contribute to defining methodological standards for the development of preventive strategies. Understanding the error represents the main effort to be made to improve the quality and safety of care. In fact, it is widely known that error is the most common and preventable cause of patient harm. The costs of medical errors are significant and include expenses due to morbidity, mortality, additional treatments, and prolonged hospital stay. On the other hand, the costs of prevention and surveillance are relatively low and sustainable [1-8]. The aim of the papers collected in the present issue is to provide relevant information about healthcare quality and patient safety, focusing attention on the adequacy of diagnostic procedures, medication errors, litigation management, risk management, and performance measurement. This special international issue of ‘Current Pharmaceutical Biotechnology’, entitled “Risk management, patient safety and quality in health care” compiles valuable research articles on subjects concerning the quality and safety of care, the evaluation of healthcare activities, and the processes of elaboration, development, and implementation of health policies.

Risk management, patient safety and quality in health care / Santurro, A.; Frati, P.; Fineschi, V.. - In: CURRENT PHARMACEUTICAL BIOTECHNOLOGY. - ISSN 1389-2010. - 22:15(2021), pp. 1962-1963. [10.2174/138920102215210928154236]

Risk management, patient safety and quality in health care

Santurro A.;Frati P.;Fineschi V.
2021

Abstract

The formulation of a correct diagnosis and the prescription of adequate therapies represent key aspects in planning healthcare. Diagnostic and therapeutic errors constitute a significant and unrecognized threat to patient safety. In such a context, the management of clinical risk represents a privileged observatory on healthcare since the successful implementation of these activities involves the search for preventive actions adequate to overcome the critical issues. The implementation of a virtuous litigation management system as well as a culture of safety for citizens and health professionals cannot be guaranteed by sectoral interventions but must derive from the integrated action of different skills. With this in mind, the integration of activities must aim at improving quality and safety with clinical risk management. These activities must be guaranteed through the most appropriate organizational methods based on the peculiarities of the individual health systems. Therefore, in the current state of knowledge, the acquisition of data from the different institutions is fundamental in order to adopt a shared methodology and design appropriate strategies for the reduction of errors in medicine. The need to generate evidence and recommendations useful for competitively addressing problems related to error requires the identification and use of evaluation criteria and performance indicators that can contribute to the continuous updating of technologies. Furthermore, the reduction of the knowledge gap and the implementation of surveillance systems at a multicenter level can contribute to defining methodological standards for the development of preventive strategies. Understanding the error represents the main effort to be made to improve the quality and safety of care. In fact, it is widely known that error is the most common and preventable cause of patient harm. The costs of medical errors are significant and include expenses due to morbidity, mortality, additional treatments, and prolonged hospital stay. On the other hand, the costs of prevention and surveillance are relatively low and sustainable [1-8]. The aim of the papers collected in the present issue is to provide relevant information about healthcare quality and patient safety, focusing attention on the adequacy of diagnostic procedures, medication errors, litigation management, risk management, and performance measurement. This special international issue of ‘Current Pharmaceutical Biotechnology’, entitled “Risk management, patient safety and quality in health care” compiles valuable research articles on subjects concerning the quality and safety of care, the evaluation of healthcare activities, and the processes of elaboration, development, and implementation of health policies.
2021
; Delivery of Health Care; Humans; Quality of Health Care; Patient Safety; Risk Management
01 Pubblicazione su rivista::01a Articolo in rivista
Risk management, patient safety and quality in health care / Santurro, A.; Frati, P.; Fineschi, V.. - In: CURRENT PHARMACEUTICAL BIOTECHNOLOGY. - ISSN 1389-2010. - 22:15(2021), pp. 1962-1963. [10.2174/138920102215210928154236]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1621367
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact